MontanerJ.S.G., ReissP., CooperD.. A randomized, double-blinded trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients – the Incas trial. Journal of the American Medical Association1998; 279: in press
2.
WongJ.K., GunthardF.G., HavlirD.V., ZhangZ.Q., HaaseA.T., IgnacioC.C., KwokS., EminiE., & RichmanD.D.Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proceedings of the National Academy of Sciences, USA1997; 94: 12574–12579
3.
CarrA., SamarasK., BurtonS., FreundJ., & ChisholmD.J.A syndrome of peripheral lipodystrophy (LD), hyperlipidemia and insulin resistance due to HIV protease inhibitors (PI's).5th Conference on Retroviruses and Opportunistic Infections, 1–5 February 1998, Chicago, USA. Abstract 410
4.
SwartzM.N.Mitochondrial drug toxicity – new adverse drug effects. New England Journal of Medicine1995; 333: 1146–1148
5.
FreimanJ.P., HelfertK.E., HamrellM.R., & SteinD.S.Hepatomegaly with severe steatosis in HIV-seropositive patients. AIDS1993; 7: 379–385
6.
SeidlinM., LambertJ.S., DolinR., & ValentineF.T.Pancreatitis and pancreatic dysfunction in patients taking dideoxyinosine. AIDS1992; 6: 831–835
7.
GulickR.M., MellorsJ.W., HavlirD., EronJ.J., GonzalezC., McMahonD., RichmanD.D., ValentineF.T., JonasL., MeibohmA., EminiE., & ChodakewitzJ.A.Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. New England Journal of Medicine1997; 337: 734–739
8.
CavertW., NotermansD.W., StaskusK., WietgrefeS.W., ZupancicM., GebhardK., HenryK., ZhangZ.Q., MillsR., McDadeH., SchuwirthC.M., GoudsmitJ., DannerS.A., & HaaseA.T.Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science1997; 276: 960–964
9.
LafeuilladeA., CholletL., HittingerG., ProfiziN., CostesO., & PoggiC.Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/ml. Journal of Infectious Diseases1998; 177: 235–238
10.
NotermansD.W., JurriaansS., de WolfF.. Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. AIDS1998; 12: 167–173
11.
RaffiF., PialouxG., Brun-VezinetF.. Results of TRILEGE trial. A comparison of three maintenance regimens for HIV-infected adults receiving induction therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). 5th Conference on Retroviruses and Opportunistic Infections, 1–5 February 1998, Chicago, USA. Abstract LB15
12.
HavlirD.V., HirschM., CollierA.. Randomized trial of indinavir (IDV), vs. zidovudine (ZDV)/lamivudine (3TC) vs. IDV/ZDV/3TC therapy. 5th Conference on Retroviruses and Opportunistic Infections, 1–5 February 1998, Chicago, USA. Abstract LB16
13.
HallD.B., MontanerJ.G.S., ReissP.. Induction-maintenance antiretroviral therapy: proof of concept. AIDS1998; 12: in press
14.
ChunT-W, CarruthL., FinziD., ShenX., DiGuiseppeJ.A., HermankovaM., ChadwickK., MargolickJ., QuinnT.C., KuoY.H., BrookmeyerR., ZeigerM.A., Barditch-CrovoP., & SilicianoR.F.Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature1997; 387: 183–188
15.
WongJ.K., HezarehM., GünthardH.F., HavlirD.V., IgnacioC.C., SpinaC.A., & RichmanD.D.Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science1997; 278: 1291–1295
16.
FinziD., HermankovaM., PiersonT., CarruthL.M., BuckC., ChaissonR.E., QuinnT.C., ChadwickK., MargolickJ., BrookmeyerR., GallantJ., MarkowitzM., HoD.D., RichmanD.D., & SilicianoR.F.Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science1997; 278: 1295–1300
17.
ChunT-W, StuyverL., MizellS.B., EhlerL.A., MicanJ.A., BaselerM., LloydA.L., NowakM.A., & FauciA.S.Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proceedings of the National Academy of Sciences, USA1997; 94: 13193–13197